June 1, 1992Journal of Interventional Cardiology
Thrombolysis for Acute Myocardial Infarction: Making Sense of The Clinical Trials Data
Why the study?
Do newer thrombolytic agents (tPA, APSAC) improve mortality compared to streptokinase in patients with acute myocardial infarction?
Population
Patients with acute myocardial infarction
Comparison
Thrombolytic therapy vs Control/placebo or active comparator
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Streptokinase remains appropriate for AMI thrombolysis; leaves open whether newer agents improve outcomes in select patients or with adjunctive strategies.
Structured PICO
Do newer thrombolytic agents (tPA, APSAC) improve mortality compared to streptokinase in patients with acute myocardial infarction?
P
Population
Patients with acute myocardial infarction
I
Intervention
Thrombolytic therapy (tissue plasminogen activator [tPA], anistreplase [APSAC], or streptokinase [SK])
C
Comparator
Control/placebo or active comparator (streptokinase)
O
Outcome
Mortality and coronary blood flow patencyhard clinical
While thrombolytic therapy reduces mortality in acute myocardial infarction, newer agents like tPA and APSAC have not demonstrated greater mortality reductions than streptokinase despite faster artery opening, highlighting the complex relationship between patency timing and survival.
Cite This Study
Jeffrey L. Anderson (1992) studied this question.